We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

49 hedge funds and large institutions have $1.43M invested in Navidea Biopharmaceuticals Inc. in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

41% more capital invested

Capital invested by funds: $1.02M → $1.43M (+$414K)

13% less funds holding

Funds holding: 56 → 49 (-7)

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
49
Holders Change
-7
Holders Change %
-12.5%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
4
Closed
12
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$39.2K
2
PFO
Pathstone Family Office
New Jersey
+$22.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$18.1K
4
WS
Wedbush Securities
California
+$15.5K
5
VF
Virtu Financial
New York
+$13.4K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$7K
2
Jane Street
Jane Street
New York
-$5K
3
SWA
Stratos Wealth Advisors
Ohio
-$5K
4
CAG
Csenge Advisory Group
Florida
-$4K
5
HighTower Advisors
HighTower Advisors
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$552K +$39.2K +13,305 +7%
BlackRock
2
BlackRock
New York
$345K +$1.03K +349 +0.3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$99K – – –
California Public Employees Retirement System
4
California Public Employees Retirement System
California
$51K – – –
WS
5
Wedbush Securities
California
$41K +$15.5K +5,250 +54%
ACM
6
Allred Capital Management
Texas
$35K +$6.45K +2,185 +21%
Citadel Advisors
7
Citadel Advisors
Florida
$35K +$18.1K +6,126 +95%
Northern Trust
8
Northern Trust
Illinois
$34K – – –
VF
9
Virtu Financial
New York
$26K +$13.4K +4,533 +94%
Morgan Stanley
10
Morgan Stanley
New York
$22K +$29 +10 +0.1%
PFO
11
Pathstone Family Office
New Jersey
$21K +$22.2K +7,525 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$19K -$631 -214 -3%
UBS Group
13
UBS Group
Switzerland
$17K +$6.3K +2,136 +52%
Cambridge Investment Research Advisors
14
Cambridge Investment Research Advisors
Iowa
$16K -$94 -32 -0.5%
Creative Planning
15
Creative Planning
Kansas
$16K – – –
Wells Fargo
16
Wells Fargo
California
$13K – – –
State Street
17
State Street
Massachusetts
$9K – – –
SFS
18
Sowell Financial Services
Arkansas
$9K +$9.66K +3,274 New
CWM
19
Cabot Wealth Management
Massachusetts
$8K – – –
Citigroup
20
Citigroup
New York
$6K – – –
SW
21
SVB Wealth
Massachusetts
$6K – – –
Tudor Investment Corp
22
Tudor Investment Corp
Connecticut
$6K – – –
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$4K – – –
JP Morgan Chase
24
JP Morgan Chase
New York
$4K – – –
LFG
25
LifePlan Financial Group
Ohio
$4K – – –
1
2 3

NAVB Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2019, worth a combined $1.43M — up 41% from $1.02M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NAVB and 5 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $39.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $7K sold.

  • 49 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2019, down from 56 in Q4 2018.
  • Funds reported $1.43M of Navidea Biopharmaceuticals Inc. stock for Q1 2019, up 41% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2019 and 12 closed out, a net change of -7 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2019 was Vanguard Group, an estimated $39.2K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2019 was Two Sigma Securities, an estimated $7K sold.

Based on aggregated 13F filings for Q1 2019.